Peer Review History
| Original SubmissionJuly 9, 2019 |
|---|
|
PONE-D-19-19063 The use of prophylactic intra-aortic balloon pump in high-risk patients undergoing Coronary Artery Bypass Grafting PLOS ONE Dear Dr Nakmaura, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Oct 11 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Andrea Ballotta Academic Editor PLOS ONE Journal Requirements: 1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating that “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript” in your financial disclosure. Please also provide the name of the funders of this study (as well as grant numbers if available) in your financial disclosure statement. Please include your amended statements within your cover letter; we will change the online submission form on your behalf. Additional Editor Comments (if provided): Thanks for your contribution but, as stated by the reviewers, the manuscript needs major revision. Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The article presents a prospective observational analysis of 99 patients (group A; 21%) at “high-risk” (out of 471) having undergone from Decembre 2005 to December 2017 either isolated or combined CABG with prophylactic IABP compared to others (Group B 79%, 372 pts). All patients with contraindications to IABP were excluded from the study. The “high risk” criteria the patient should have a stable hemodynamics with 2 criteria out of 6 (NYHA III or IV; LVEF<40%; LVEDD>65mm; LM stenosis >50%; a diffuse CAD defined as more than three distal or more anastomosis and refractory unstable angina. IABP were inserted the day before operation in CathLab from femoral artery and with a subsequent pre and postoperatively ICU monitoring. Primary endpoint: 30D mortality Secondary endpoint: major postoperative complications (LCO, postoperative MI; bleeding; stroke; postoperative AF; IOT>72hh; ICU stay >7dd; total postoperative days >30 dd and MACCE. Forty seven pts in Group B required IABP postoperatively. Mean follow up was 32 months. The two groups were significantly different for LVEF, NYHA class, LM disease; emergent operation and number of stenosis but similar for age, sex, BMI and other comorbidities. Hemodialysis and current smoker were higher in Group B. The results show similar intraoperative results (time, conversion, postop bleeding, transfusion and strokes). In the postoperative results Group A had a longer mechanical ventilation and ICU stay. No complications are reported for the support of IABP. Overall impatient mortality was 2.1% (2% in group A) (30d 2% Group A vs 1.4% Group B) and no differences in terms of death and MACCE were found. In the discussion section the authors explain their clinical results and their strategies: - a multidisciplinary team of cardiologists, cardiac surgeons, nurses, rehabilitation staff, and medical engineers met to outline a detailed treatment plan for patients - all non-urgent patients underwent extensive cardiac rehabilitation prior to surgery, even patients that were admitted into the emergency room - all patients underwent treated dental conditions, glycemic imbalances, and co-morbid treatable diseases such as carotid artery stenosis prior to cardiac surgery. - post-operatively a prolonged hospitalization were used to monitor patient’s progress using a coronary angiogram and echocardiography. - The authors, in the end, stated that prophylactic IABP in the high-risk patient undergoing CABG is an acceptable option Even if the article is interesting, the results are unremarkable and is a hot topic, in my opinion some issues must be solved and more details must be added. - Patients selection is the key of this article and in my opinion the authors must evaluate just isolated CABG and not combinated ones. Furthermore is not clear the types of operations in each group. - Surgical description is very poor and there is no mention about conduits and surgical techniques. - In my opinion the evaluation of the “high risk” patients is not correct in this population. The use of the definition of Ding et al could be useful only in OPCABG because includes technical aspects of off pump surgery, beyond the clinical features, that is inconsistent during ONCABG. Less than 50% of patients underwent OPCABG in your population. - Your clinical strategy leads to a strict preoperative selection and preparation of patients and even if it is probably very far from my clinical practice I would like to better understand it. So from the first access to the hospital how long do you take for the “exstensive rehabilitation” and which are your endpoints? this strategy also adapt to patients with left main stenosis? You didn’t clarify how many AMI (recent of previous) was present in your population. Probably another interesting evaluation could be made on your strategy for carotid stenosis treatment: how many patients received a surgical or endovascular treatment of the carotid arteries in your population and how long before? - What about postoperative AKI? - There is no mention about conduction and completeness of FU. - In my opinion an actuarial survival estimated by KM analysis has very little sense in a period of observation of 30 days. It should be made on the first year at least. - The topic is hot and the consensus on the benefit of prophylactic IABP is not so widespread. So in my opinion could be important to emphasize the open question in the discussion section and the references must be enlarged. Furthermore the recent article from Rampersad et al is not a RCT but a metaanalysis. - The tables are very difficult to read, please reorganize and simplify Reviewer #2: Thank you for your paper. It is a very interesting field because IABP seems has to be abandoned by cardiological guidelines but still it has been use consistently in cardiac surgery As you underlined the cohort of patients in not very wide and is not possible to be definitive on the prophylactic IABP with this numbers Where do you allocate the patient in the preoperative period? has to be at least an HDU. Has this time counted in the ICU admission stay? In my institution we insert the IABP after the induction in OR. It seems that the method you have used to detect high risk patients is not working properly since there is a consistent use in not high risk group. Plus is very interesting that the high risk LVEF, despite is significantly different from the other group, is 49%. The last consideration is on the weaning time. Have you got any standard parameter to consider to asses the possibility to wean? Do you you use levosimendan? ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
The use of prophylactic intra-aortic balloon pump in high-risk patients undergoing Coronary Artery Bypass Grafting PONE-D-19-19063R1 Dear Dr. Nakmaura, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Andrea Ballotta Academic Editor PLOS ONE Additional Editor Comments (optional): Thank you again for your efforts, i deem your paper suitable for publication. Reviewers' comments: |
| Formally Accepted |
|
PONE-D-19-19063R1 The use of prophylactic intra-aortic balloon pump in high-risk patients undergoing Coronary Artery Bypass Grafting Dear Dr. Nakmaura: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Andrea Ballotta Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .